会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • CHOLESTERIC LIQUID CRYSTAL DRYING PROCESS AND SOLVENT
    • 液体液晶干燥工艺和溶剂
    • WO2004076588A1
    • 2004-09-10
    • PCT/US2004/000549
    • 2004-01-12
    • 3M INNOVATIVE PROPERTIES COMPANYSOLOMONSON, Steven, D.RADCLIFFE, Marc, D.POKORNY, Richard, J.
    • SOLOMONSON, Steven, D.RADCLIFFE, Marc, D.POKORNY, Richard, J.
    • C09K19/52
    • C09K19/52
    • The invention provides methods of forming a cholesteric liquid crystal layer that include forming a cholesteric liquid crystal composition, depositing the cholesteric liquid crystal composition onto a substrate, and initially drying the cholesteric liquid crystal composition at a temperature at or below about 90 °C so that the cholesteric liquid crystal composition has at least 80 % solids remaining. The invention also provides methods of forming a cholesteric liquid crystal layer that include forming a cholesteric liquid crystal composition, depositing the cholesteric liquid crystal composition onto a substrate, and initially drying the cholesteric liquid crystal composition at a temperature at or below about 90 °C, wherein the drying is accomplished using a technique that provides little or no airflow. The invention further provides a cholesteric liquid crystal composition that includes at least one cholesteric liquid crystal precursor and 1,3-dioxolane.
    • 本发明提供了形成胆甾型液晶层的方法,其包括形成胆甾醇型液晶组合物,将胆甾型液晶组合物沉积在基板上,并且在约90℃或低于约90℃的温度下开始干燥胆甾型液晶组合物,使得 胆甾型液晶组合物残留有至少80%的固体。 本发明还提供了形成胆甾型液晶层的方法,其包括形成胆甾醇型液晶组合物,将胆甾型液晶组合物沉积在基材上,并且在约90℃或更低的温度下最初干燥胆甾型液晶组合物, 其中使用提供很少或没有气流的技术来实现干燥。 本发明还提供一种胆甾型液晶组合物,其包括至少一种胆甾型液晶前体和1,3-二氧戊环。
    • 9. 发明申请
    • CHOLESTERIC LIQUID CRYSTAL COPOLYMERS AND ADDITIVES
    • WO2005023964A3
    • 2005-03-17
    • PCT/US2004/021610
    • 2004-07-06
    • 3M INNOVATIVE PROPERTIES COMPANY
    • RADCLIFFE, Marc, D.POKORNY, Richard, J.SPAWN, Terence, D.SOLOMONSON, Steven, D.
    • C09K19/40
    • A cholesteric liquid crystal composition includes a) a cholesteric liquid crystal compound or a cholesteric liquid crystal precursor; and b) a compound of formula (I), formula (II) or formula (III): where, n is 1, 2, 3, or 4; m is 1, 2, or 3; R is an acrylate, methacrylate, acrylamide, isocyanate, epoxy, or silane; R 1 is a (C 3 -C 8 ) alkylene, (C 3 -C 8 ) alkenylene, or (C 3 -C 8 ) alkylyne; R 2 is a bond, -O-, -C(O)O-, -O(O)C-, -OC(O)O-, -C(O)N-, -CH=N-, -N=CH-, or -NC(O)-; R 3 is a cycloalkylene, cycloalkenylene, heterocyclylene, arylene, or hetroarylene; R 4 is a bond, (C 1 -C 8 ) alkylene, (C 2 -C 8 ) alkenylene, (C 2 -C 8 ) alkylyne, carbonyl, -O-, -C(O)O-, -O(O)C-, -OC(O)O-, -C(O)N-, -CH=N-, -N=CH-, or -NC(O)-; R 5 is a bond, cycloalkylene, cycloalkenylene, hetrocyclylene, arylene, or hetroarylene; R 6 is hydrogen, cyano, halo, (C 1 -C 8 ) alkoxy, (C 1 -C 8 ) alkyl, nitro, amino, carboxy, mercapto, (C 1 -C 4 )thioalkyl, COCH 3 , CF 3 , OCF 3 , or SCF 3 ; R 7 is a (C 1 -C 2 ) alkylene, (C 2 ) alkenylene, or (C 2 ) alkylyne; R 8 is is hydrogen, halo, (C 1 -C 8 ) alkoxy, (C 1 -C 8 ) alkyl, nitro, amino, carboxy, mercapto, (C 1 -C 4 )thioalkyl, COCH 3 , CF 3 , OCF 3 , or SCF 3 , R 9 is a cycloalkylene, cycloalkenylene, heterocyclylene, arylene, or hetroarylene; and R 10 is a (C 1 -C 8 ) alkylene, (C 2 -C 8 ) alkenylene, or (C 2 -C 8 ) alkylyne.